All Studies Meta Analysis

Treatment with Ivermectin Increases the Population of Bifidobacterium in the Gut

Hazan et al., ACG 2023

Oct 2023

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 111 treatments. c19ivm.org

Analysis of the effect of ivermectin on the gut microbiome, showing a significant increase in Bifidobacterium.

Bifidobacterium plays a key role in the immune system, for example enhancing antibody production, facilitating the induction of regulatory T cells, modulating the immune response of macrophages, dendritic cells, and T cells, maintaining gut barrier integrity, and inhibiting harmful microbes.

Increased Bifidobacterium is associated with lower COVID-19 severity1.

Important missing comments or errors? Let us know.

Study covers probiotics and ivermectin.

1. Taufer et al., The Role of Bifidobacterium in COVID-19: A Systematic Review, Life, doi:10.3390/life13091847.mdpi.com, doi.org.

Hazan et al., 22 Oct 2023, preprint, 4 authors.

This Paper Ivermectin All

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0